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MaCurrent practice guidelines advocate culprit vessel intervention alone in patients with ST-segment elevation myocardial
infarction (STEMI) found to have multivessel coronary disease during primary percutaneous coronary intervention (PCI).
The debate on the timing of noninfarct artery intervention has recently been reinvigorated by the PRAMI (Preventive
Angioplasty in Acute Myocardial Infarction) trial, in which patients undergoing preventive PCI of signiﬁcant nonculprit
lesions at the time primary PCI for STEMI had reduced rates of cardiac death, nonfatal myocardial infarction, and re-
fractory angina. Given that previous literature has cautioned against multivessel PCI during STEMI, this raises the
question of whether technical and pharmacological advances in PCI may have opened the door to safely revisit this issue
with additional clinical rigor. The impact of STEMI pathophysiology on nonculprit vessel plaque, how treatment of
nonculprit lesions alters the natural history of coronary disease after STEMI, and whether this results in a clinical beneﬁt
remain unclear, and much of the existing data are retrospective. Additionally, the PRAMI trial did not include a staged PCI,
leaving questions as to how this approach might fare compared with simultaneous preventive PCI. In this review, we
discuss the pathophysiology of nonculprit vessel plaque in STEMI, provide a summary of the existing literature on the
topic, and discuss the PRAMI trial in the face of previous data and possible future directions for further study. (J Am Coll
Cardiol Intv 2015;8:131–8) © 2015 by the American College of Cardiology Foundation.T imely treatment of the culprit lesion in acuteST-segment elevation myocardial infarction(STEMI) is essential to minimizing myo-
cardial necrosis, curbing recurrent ischemia, and
reducing mortality (1). Primary percutaneous coro-
nary intervention (PCI) is the gold standard for resto-
ration of blood ﬂow in the infarct artery (2). STEMI
patients with multivessel (MV) coronary artery dis-
ease (CAD) have higher mortality rates and a higher
incidence of recurrent myocardial infarction (MI)
than patients with single-vessel CAD, and the pres-
ence of triple-vessel CAD diagnosed during MI por-
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CAD = coronary artery disease
CI = conﬁdence interval
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
MV = multivessel
NNT = number needed to treat
OR = odds ratio
PCI = percutaneous
intervention
STEMI = ST-segment elevation
myocardial infarction
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132however, several strategies are widely used
for STEMI patients with additional obstruc-
tive plaques after successful culprit lesion
PCI: immediate coronary stenting, staged
PCI, and medical therapy only. Advances in
interventional technologies, increased oper-
ator experience, and improved pharmaco-
therapies have made PCI safer and effective
in high-risk circumstances. Coupled with
emerging literature that questions current
guidelines, these factors have opened the
door to revisit this clinical dilemma and sug-
gest that this contentious area may not be
immune to change (9).
The debate regarding the appropriate
strategy has recently intensiﬁed in light of
the PRAMI (Preventive Angioplasty inMyocardial Infarction) trial, in which Wald et al. (9)
studied PCI in nonculprit coronary lesions at the
time of primary PCI for STEMI, a practice they termed
“preventive stenting.” In contrast to current guide-
lines and the studies that informed them (10–13), the
PRAMI investigators demonstrated that in patients
undergoing primary PCI for STEMI, the combined rate
of cardiac death, nonfatal MI, and refractory angina
(deﬁned as angina despite medical therapy supported
by objective evidence of ischemia including electro-
cardiographic changes during a spontaneous episode
of pain, a positive stress test result, or pressure-wire
assessment) was reduced by 65% in the preventive
PCI group, with an absolute risk reduction of 14%,
compared with the group that did not undergo addi-
tional stenting (9). However, only 2 strategies were
tested: simultaneous, preventive PCI of nonculprit
vessel obstructive disease versus culprit vessel
revascularization only. There was no arm for non-
culprit vessel staged PCI.
Naturally, this investigation has raised a variety of
intriguing questions. Does more complete revascu-
larization overcome any adverse effects of treating
nonculprit lesions in the acute setting? What are the
pathophysiological principles at play during STEMI,
and how are nonculprit vessel plaques affected? Does
targeting such mechanisms via PCI offer a clinical
beneﬁt, and how might this change the natural his-
tory of nonculprit obstructive disease in the imme-
diate aftermath of acute coronary syndromes (ACS)?
Why are the ﬁndings in the PRAMI trial so contrary to
what we already know? If MV-CAD is present during
STEMI and an aggressive strategy is preferred, does
the timing of the subsequent PCI make a difference?
Cautioning against treating multiple vessels during
STEMI, especially in patients without hemodynamic
compromise, the guidelines, in part, originate fromsafety concerns related to increased complications
of an MV intervention. Potential drawbacks of a
preventive strategy include operating in an inﬂam-
matory and prothrombotic milieu, which may lead
to overestimation of nonculprit lesion severity,
increased procedural risk, and increased incidence
of stent thrombosis (10). MV-PCI also leads to
more contrast use and may place several myocardial
territories at risk should unforeseen complica-
tions occur (9,10). However, it may be that the path-
ophysiological milieu of acute STEMI alters the
behavior of noninfarct lesions, rendering interven-
tion beneﬁcial. The contemporary literature relating
to this clinical context is largely indirect in its inves-
tigation, retrospective in its analysis, and contradic-
tory in its ﬁndings (10–18). The PRAMI trial questions
the current practice guidelines and obliges us to re-
examine the existing evidence.
PATHOPHYSIOLOGY
The higher morbidity and mortality seen in STEMI
patients with MV-CAD are likely multifactorial and
include the presence of diffuse atherosclerosis as a
harbinger of plaque instability, total ischemic burden,
and impaired contractility of non-infarct zones in the
presence of multiple obstructive stenosis (5). When
examining the role of preventive PCI and more com-
plete revision in the context of STEMI, one must
consider the impact of these factors to determine how
an aggressive strategy may offer clinical beneﬁt.
Autopsy and natural history studies demonstrate
that most ACS result from the loss of integrity of a thin
ﬁbrous cap overlying atherosclerotic plaque, either
from rupture or erosion (5,19–22). Factors such as the
inﬂammatory cascade, which instigates weakening of
the ﬁbrous cap, catecholamine-mediated intraluminal
mechanical forces, and heightened sympathetic tone,
operate beyond the culprit lesion, effecting nonculprit
plaque and the hemodynamics of nonculprit coronary
arteries (19,23,24). Patients with acute myocardial
infarction are also more likely to harbor multiple
complex coronary plaques that are associated with
adverse clinical outcomes, and themajority of patients
who die of MI have more than 1 culprit lesion (5,25).
Taken together, these ﬁndings suggest that acute
myocardial infarction reﬂects more generalized pa-
thophysiological derangements of endothelial dys-
function, coagulation, and inﬂammation, with the
potential to impair coronary perfusion beyond the
culprit lesion distribution and destabilize plaque
throughout the coronary vasculature (5,26,27).
Perhaps the beneﬁt seen in the PRAMI trial reﬂects the
impact of stabilizing such vulnerable plaques with PCI.
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133As the PROSPECT (Predictors of Response to CRT)
study demonstrated, however, high-risk plaque need
not be obstructive. Of the 106 nonculprit lesions
determined to be responsible for major adverse car-
diovascular events (MACE) in the follow-up of pa-
tients with previous ACS, the mean angiographic
percentage of stenosis was 32.3  20.6% (21). Many
of these lesions were angiographically inconspicuous.
These ﬁndings suggest that nonculprit lesions
causing recurrent events in PROSPECT study were
unlikely to have been targeted for preventive PCI by
PRAMI criteria (>50% angiographic stenosis). If not
plaque vulnerability, what other mechanisms may
account for the clinical beneﬁt seen in the PRAMI
trial? Possibilities include reduction of residual and
border zone ischemia, improved pump function of
noninfarct areas, and more favorable ventricular
remodeling. In the TAMI (Thrombolysis and Angio-
plasty in Myocardial Infarction) study (4), patients
with MV disease had lower ejection fractions com-
pared with patients with single-vessel disease. This
was attributed to noninfarct zone function, hyperki-
netic in the group with single-vessel disease, but in
some cases, hypocontractile or dyskinetic in those
with MV-CAD. However, we do not know whether
these mechanisms were operating in the PRAMI trial
patients.
THE LITERATURE
Our review of the existing literature was similar to the
method used more formally in the meta-analysisTABLE 1 Data From Prospective Trials
Di Mario et al. (31) Polit
Study design Multicenter RCT Single-center
No. of subjects 69 214
Comparator groups COR
MV-PCI
COR
Staged PCI
MV-PCI
In-hospital mortality COR, 0% vs. MV-PCI, 1.9%
(p ¼ 0.754)
COR, 8.3% vs
MV-PCI, 3
Long-term mortality At 1 yr: COR, 0% vs. MV-PCI,
1.9% (p ¼ 0.754)
At 2.5 yrs: CO
PCI, 6.2%
(p ¼ 0.17)
Other outcomes MACE at 1 yr: COR, 35.3% vs.
MV-PCI, 21.1% (p ¼ 0.33)
Repeat revascularization or CABG:
COR, 35.3% vs. MV-PCI, 17.3%
(p ¼ 0.174)
MACE at 2.5 y
staged PC
23.1% (p <
Repeat revasc
COR, 33.3% v
vs. MV-PC
CABG ¼ coronary artery bypass graft; CI ¼ conﬁdence interval; COR ¼ culprit artery
MV-PCI ¼ multivessel percutaneous coronary intervention (index procedure); RCT ¼ ranrecently published by Zhang et al. (28). In general,
we reviewed studies that included the following: 1) a
population of STEMI patients with MV disease; 2) PCIs
encompassing both the culprit vessel PCI and MV-PCI;
3) MV-PCI performed during the index procedure or
within a speciﬁc time period for a staged interven-
tion; and 4) pertinent endpoint data.
RETROSPECTIVE. PCI of a noninfarct artery with
Thrombolysis In Myocardial Infarction ﬂow grade 3
at the time of primary PCI in hemodynamically sta-
ble patients has been associated with worse clinical
outcomes in several studies (10–13), although others
suggest that it may be performed safely (Table 1)
(14–18). The approach advocated by the guidelines
stems largely from registry data. In the HORIZONS-
AMI (Harmonizing Outcomes with RevasculariZa-
tiON and Stents in Acute Myocardial Infarction)
trial, MV-PCI performed at the time of the primary
PCI for STEMI was associated with higher 1-year
mortality (9.2% vs. 2.3%, p < 0.0001), cardiac mor-
tality (6.2% vs. 2.0%, p ¼ 0.005), stent thrombosis
rate (5.7% vs. 2.3%, p ¼ 0.02), and a trend toward
greater MACE (18.1% vs. 13.4%, p ¼ 0.08) than
staged PCI. A staged strategy was independently
associated with lower all-cause mortality at 30 days
and 1 year (13).
Hannan et al. (10) reviewed the New York State
experience in this context. STEMI patients with MV
disease undergoing PCIs in New York State over a
3-year period were subdivided into the following 4
therapeutic categories: 1) culprit vessel PCI alone;
2) MV-PCI during the index procedure; 3) PCI duringi et al. (30)
Wald et al. (9)
(PRAMI) Ochala et al. (33)
RCT Multicenter RCT Single-center RCT
465 92
Preventive PCI (MV-PCI)
No preventive PCI (COR)
Culprit vessel PCI
MV-PCI
. staged PCI, 0% vs.
.1% (p ¼ 0.037)
Not reported Culprit vessel PCI, 0% vs.
MV-PCI, 0%
R, 15.5% vs. staged
vs. MV-PCI, 9.2%
At 23 months: MV-PCI, 1.7%
vs. COR, 4.3% (p ¼ 0.07)
At 6 months: culprit vessel PCI, 0%
vs. MV-PCI, 0%
rs: COR, 50.0% vs.
I, 20.0% vs. MV-PCI,
0.001)
ularization:
s. staged PCI, 12.3%
I 9.2% (p < 0.001)
Noncardiac mortality at 3 yrs:
MV-PCI, 3.4% vs. COR, 2.6%
(p ¼ 0.86)
Repeat revascularization:
MV-PCI, 16% vs. COR, 19.9%
(HR: 0.30, 95% CI: 0.17–0.56;
p < 0.001)
The study was not powered to assess
the MACE
Results supported the following
hypothesis that multivessel,
complete 1-stage PCI in patients
with STEMI and MVD leads to
quicker and more substantial
improvement of LVEF compared
with standard 2-stage PCI
only revascularization; HR ¼ hazard ratio; MACE ¼ major adverse cardiac events; MVD ¼ multivessel disease;
domized, controlled trial; STEMI ¼ ST-segment elevation myocardial infarction.
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134the index admission; or 4) staged MV-PCI within
60 days of the index admission. Patients with
cardiogenic shock were excluded. For patients
without hemodynamic compromise, left ventricular
ejection fraction <20% or malignant ventricular
arrhythmia, culprit vessel PCI was associated with
lower in-hospitality mortality than MV-PCI during the
index procedure (0.9% vs. 2.4%, p ¼ 0.04), results
that trended toward signiﬁcance at 24 and 42 months.
Patients undergoing staged MV-PCI during the index
admission experienced lower mortality rates at 12, 24,
and 42 months compared with culprit vessel PCI
alone, but none of the differences reached statistical
signiﬁcance. However, patients undergoing staged
MV-PCI within 60 days after the index procedure had
a signiﬁcantly lower 12-month mortality rate than
patients undergoing culprit vessel PCI only (1.3% vs.
3.3%, p ¼ 0.04). No statistical analysis comparing
patients undergoing staged MV-PCI during the index
admission versus within 60 days after the index
procedure was performed. This study suggests that a
complete revision strategy, addressed in a staged
manner, may be associated with improved clinical
outcomes (29).
Registry data, however, remain inconclusive. Qar-
awani et al. (14) reported that complete revision
during the primary PCI is associated with a reduced
incidence of MACE (recurrent ischemia, reinfarction,
heart failure, and in-hospital mortality) during the
index hospitalization (16.7% vs. 52%, p ¼ 0.0001),
although transient renal dysfunction was observed
more frequently (8.4% vs. 4%, p ¼ 0.01). Other
studies have suggested that MV-PCI in STEMI pa-
tients may help to limit infarct size (15). In a large
meta-analysis comparing MV revascularization with
culprit vessel revascularization in 61,764 STEMI pa-
tients with MV-CAD, Bangalore et al. (18) reported
that for early outcomes (<30 days), there was no
signiﬁcant difference in mortality, MI, stroke, and
target vessel revascularization, although there was a
44% decrease in risk of repeat PCI in patients un-
dergoing MV revascularization. Likewise, for long-
term outcomes (follow-up of 2.0  1.1 years), there
was no difference in MI, target vessel revasculariza-
tion, or stent thrombosis. However, the risk of
mortality, repeat PCI, and coronary artery bypass
graft decreased by 33%, 43%, and 53%, respectively
with MV revascularization. Although some studies
have supported these results (17), others have drawn
contradictory conclusions, as shown by a contempo-
rary meta-analysis that reported that MV-PCI was
associated with a 60% higher risk of long-term mor-
tality than culprit vessel PCI (odds ratio [OR]: 1.6, 95%
conﬁdence interval [CI]: 1.3 to 2.0) (12). MV-PCI wasalso associated with higher long-term mortality than
staged PCI (OR: 2.88, 95% CI: 1.73 to 4.89, p ¼ 0.001).
PROSPECTIVE, RANDOMIZED TRIALS. The results of
prospective studies before the PRAMI trial are
underpowered to show a mortality difference.
Although combined results of 9 cohort studies in-
volving 5,128 patients suggested higher long-term
mortality after MV-PCI compared with culprit
vessel PCI (OR: 1.8, 95% CI: 1.4 to 2.2), the collective
results of the 288 patients analyzed in a randomized
fashion did not show a difference in long-term
mortality (OR: 0.7, 95% CI: 0.3 to 1.6) (12). A review
of the prospective, randomized trial literature,
however, reveals only a small number of existing
trials, each with a small number of patients (Table 2)
(30,31). The largest of these prospective trials and
ﬁrst to test 3 treatment strategies (compared with 2
in the PRAMI trial) randomized 214 patients with
STEMI and MV-CAD to the following: 1) culprit
vessel PCI alone; 2) staged PCI; or 3) simultaneous
PCI of all signiﬁcant stenoses (deﬁned as >70% of
visually estimated diameter stenosis of $2 epicar-
dial coronary arteries or their major branches) (30).
Exclusion criteria were similar to those of the PRAMI
trial. After a mean follow-up of 2.5 years, in patients
with multiple coronary lesions treated with primary
PCI, MV revascularization had a better outcome than
culprit lesion PCI only, both with a simultaneous
and staged treatment strategy. Event rates, however,
were driven by repeat revascularization as there
was no signiﬁcant difference in reinfarction rate or
mortality. The mortality rates after staged PCI
versus simultaneous MV-PCI versus culprit vessel–
only PCI were 6.2%, 9.2%, and 15.5%, respectively
(p < 0.17).
The PRAMI trial was a multicenter randomized trial
that enrolled 465 patients with STEMI who under-
went infarct-artery PCI and were then randomized
to preventive PCI (n ¼ 234) of any additional
angiographically signiﬁcant lesions (>50% diameter
stenosis) or no additional intervention (n ¼ 231).
There was no staged arm, and patients and physicians
were not blinded to the enrollment arm. Both groups
received appropriate medical therapy. Patients with
cardiogenic shock, previous coronary artery bypass
graft, surgical MV disease, and noninfarct chronic
total occlusion were excluded. Interestingly, the
majority of AMIs involved the inferior wall. Over the
23-month follow-up period, the combined incidence
of cardiac death, nonfatal MI, and refractory angina
occurred in 21 preventive PCI patients compared with
53 culprit vessel intervention–only patients. In other
words, the primary outcome was reduced by 65%,
TABLE 2 Data From Retrospective Trials or Post-Hoc Analyses
Hannan et al. (10) Toma et al. (11) Vlaar et al. (12) Qarawani et al. (14) Kornowski et al. (13) Navarese et al. (17) Bangalore et al. (18) Cavender et al. (38)
Study design Retrospective
New York State
database review
Post-hoc analysis of
RCT (APEX-AMI)
Pairwise and network
meta-analysis
Retrospective cohort,
single center
Post-hoc analysis of
RCT (HORIZONS-
AMI)
Meta-analysis Meta-analysis Retrospective
NCDR database,
multicenter
No. of subjects 3,521 2,201 40,280 120 668 27,047 61,764 28,936
Comparator
groups
COR
MV-PCI Staged PCI
COR
MV-PCI
COR
MV-PCI
Staged PCI
COR
MV-PCI
COR
Staged PCI
COR
MV-PCI
COR
MV-PCI
COR
MV-PCI
Short-term
mortality
COR, 0.9% vs.
MV-PCI, 2.4%
(p ¼ 0.04)
COR, 5.6% vs. MV-PCI,
12.5% (p < 0.001)
COR vs. MV-PCI
(OR: 0.66,
95% CI: 0.48–0.89,
p ¼ 0.007)
COR, 4% vs. MV-PCI,
4.2% (p > 0.05)
Not reported MV-PCI vs. COR
(OR: 1.30,
95% CI: 0.79–2.12,
p ¼ 0.31)
MV-PCI vs. COR
(OR: 0.79,
95% CI: 0.46–1.35,
p ¼ 0.024,
I2 ¼ 47.7%)
MV-PCI vs. COR
Excluding patients
with CS (OR: 1.23,
95% CI: 0.94–1.61,
p ¼ 1.23)
Including patients
with CS (OR: 1.54,
95% CI: 1.22–1.95,
p < 0.01)
Long-term
mortality
COR, 1.3% vs.
staged PCI, 3.3%
(p ¼ 0.04)
Not reported COR vs. MV-PCI
(OR: 0.63,
95% CI: 0.46–0.86,
p < 0.001)
COR, 8% vs. MV-PCI,
9.4% (p ¼ 0.06)
Staged PCI, 2.3% vs.
COR, 9.2% (RR: 4.10,
95% CI: 1.93–8.86,
p < 0.001)
MV-PCI vs. COR
(OR: 1.17,
95% CI: 0.86–1.58,
p ¼ 0.31)
MV-PCI vs. COR
(OR: 0.78,
95% CI: 0.54–1.11,
p ¼ 0.018,
I2 ¼ 50.9%)
Data not available
because maximal
follow-up for
this study was
in-hospital only
Other outcomes Not reported Not reported Not reported Recurrent ischemia,
reinfarction, acute
heart failure, and
in-hospital mortality.
MV-PCI, 16.7% vs. COR,
52% (p ¼ 0.0001)
MACE at 1 yr: staged
PCI, 13.4% vs. COR,
18.1% (RR: 1.42,
95% CI: 0.96–2.10,
p ¼ 0.08)
Revascularization
at 1 yr: MV-PCI vs.
COR (OR: 0.47,
95% CI: 0.28–0.78,
p ¼ 0.31)
Long-term MACE:
MV-PCI vs. COR
(OR: 0.60,
95% CI: 0.33–1.08,
p for interaction
<0.001, I2 ¼ 80.5%)
Not reported
APEX-AMI ¼ Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction; CS ¼ cardiogenic shock; HORIZONS-AMI ¼ Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction; NCDR ¼ National Cardiovascular Data
Registry; RR ¼ relative risk; other abbreviations as in Table 1.
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136with an absolute risk reduction of 14% (hazard ratio:
0.35, 95% CI: 0.21 to 0.58, p < 0.001). The beneﬁt was
similar in magnitude and remained statistically sig-
niﬁcant when the analysis was limited to the com-
bined endpoint of cardiac death and nonfatal MI
(hazard ratio: 0.36, 95% CI: 0.20 to 0.57, p ¼ 0.004),
although the absolute number of deaths was small
(4 in the preventive PCI group and 10 in culprit vessel
intervention alone). Procedure time, ﬂuoroscopy
dose, and contrast volume were increased in the
preventive PCI group, but complication rates (e.g.,
procedure-related stroke, bleeding requiring trans-
fusion or surgery) and contrast-induced nephropathy
requiring dialysis were similar between the 2 groups.
Additionally, despite concerns regarding the pro-
thrombotic and inﬂammatory milieu present in the
early phase of STEMI, there was no difference in the
stent thrombosis rate (9,13).
SUMMARIZING THE LITERATURE
Despite worse outcomes in patients with STEMI and
MV-CAD, no clear beneﬁt of complete revision over
culprit lesion revascularization only has been
demonstrated thus far. Because of the observational
and retrospective nature of these studies, revascu-
larization strategies were chosen using varying
criteria that were not prospectively deﬁned and are
undoubtedly inﬂuenced by patient and operator
characteristics. This may lead to signiﬁcant selection
bias. The prospective literature is scant, but evolving.
A recent meta-analysis by Sardar et al. (32) that in-
corporates 3 randomized trials including the PRAMI
trial revealed that an MV-PCI strategy signiﬁcantly
reduced the risk of MI (OR: 0.33, 95% CI: 0.16 to 0.69,
p ¼ 0.003, number needed to treat [NNT] ¼ 17), repeat
revascularization (OR: 0.28, 95% CI: 0.18 to 0.45, p <
0.0001, NNT ¼ 6.6) and major adverse cardiac events
(OR: 0.26, 95% CI: 0.17 to 0.38, p < 0.00001, NNT ¼ 4)
versus culprit vessel–only intervention. ORs for all-
cause mortality and cardiac mortality showed a
trend toward beneﬁt (32). The most recently pub-
lished meta-analysis on this topic by Zhang et al. (28)
included 14 randomized and nonrandomized studies
and showed worse short- (OR: 0.50, 95% CI: 0.32 to
0.77, p ¼ 0.002) and long-term (OR: 0.52, 95% CI: 0.36
to 0.74, p < 0.001) mortality with MV-PCI, thus sup-
porting current guidelines. However, a number of the
included studies were suboptimally designed and had
considerable confounding. Although the PRAMI trial
is the largest prospective study to date, it was highly
selective in its enrollment with 2,428 patients
screened and only 465 enrolled over a 5-year period.
The lack of a staged arm after the primaryintervention is a signiﬁcant difference between the
PRAMI trial and previous observations. Due to het-
erogeneous designs, populations, outcome measures,
and follow-up times, comparison of existing litera-
ture is difﬁcult.
TIMING OF PCI
Only a few published analyses have examined the
optimal timing strategy for MV-PCI in patients with
STEMI. In the randomized study performed by Politi
et al. (30), staged revascularization of the noninfarct
artery was performed at 56.8  12.9 days after the
index procedure. There was no signiﬁcant difference
in mortality rate or MACE rate between staged PCI
and the complete revision during culprit vessel
intervention, although the sample sizes studied were
too small to draw meaningful conclusions. Ochala et
al. (33) compared MV-PCI with staged PCI in 92 pa-
tients with ﬁndings suggesting a quicker improve-
ment in left ventricular function with MV-PCI during
the index procedure compared with staged revascu-
larization. Much of the literature is neutral, with no
outcomes showing beneﬁt of simultaneous MV-PCI
over a staged procedure (15,18). However, other
studies have demonstrated that a staged PCI strategy
is associated with improved short- and long-term
outcomes including all-cause mortality compared
with simultaneous revascularization (10,13).
PRACTICAL AND FUTURE CONSIDERATIONS
If a decision to intervene is made, the appropriate and
optimal timing of a nonculprit vessel preventive
procedure is unknown. Emergent MV-PCI may be
necessary in some STEMI patients who have complex
CAD with cardiogenic shock and who do not improve
after culprit lesion PCI, a strategy supported by the
current guidelines (7). Evidence supporting this
strategy, however, is lacking. The SHOCK (SHould we
emergently revascularize Occluded Coronaries in
cardiogenic shocK?) trial suggests that culprit lesion
revascularization alone is superior to MV-PCI in terms
of 1-year survival (55% vs. 20%, p ¼ 0.048) (34). What
about the patient inadequately stabilized by culprit
vessel PCI alone? Certainly consideration must be
given to the clinical context, patient comorbidities,
and the coronary anatomy if a strategy of preventive
PCI is chosen. Although the PRAMI trial demonstrated
that immediate MV-PCI offers a clinical beneﬁt
compared with only culprit vessel intervention, the
ﬁndings have been met with skepticism among the
medical community about a variety of concerns. The
study did not compare immediate with staged PCI.
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137The generalizability of the results is questionable
given that the majority of infarctions were of the
inferior wall, and nonculprit vessel intervention was
predominantly performed on the left anterior
descending artery. It is also unclear whether the
culprit vessel–only PCI group had appropriate follow-
up. This may have affected outcomes because these
patients probably stood to beneﬁt most from closely
monitored medical therapy. Furthermore, the angio-
graphic criteria for nonculprit vessel intervention are
considerably more inclusive than the conventional
criteria (>70% stenosis) used in most studies. Finally,
we are left to speculate about the causal relationship
between residual lesions in the control group and
events.
Without this information, a mechanistic explana-
tion remains elusive. If using a more conservative
strategy, can we apply what is known about the nat-
ural history of nonculprit lesion obstructive CAD? The
literature is clear in its view of PCI in stable,
obstructive CAD. Data from the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation) trial in support of optimal medical
therapy suggest that a noninvasive management
strategy is preferred in patients with stable disease
(35). The FAME (Fractional Flow Reserve versus
Angiography for Guiding Percutaneous Coronary
Intervention) trials, by demonstrating a reduction in
risk of repeat revascularization and decreasing
angina, encourage the use of PCI for hemodynami-
cally signiﬁcant stenoses, deﬁned by fractional ﬂow
reserve (36,37). The COURAGE, FAME, and FAME-2
(Fractional Flow Reserve versus Angiography for
Guiding Percutaneous Coronary Intervention-2) trials
included patients with recent STEMI, so concluding
that patients with STEMI possess otherwise typical
CAD in nonculprit vessels may be presumptuous.Last, the feasibility of identifying speciﬁc lesions for
which preventive PCI in the context of STEMI may
lead to improved outcomes is undetermined. Perhaps
hemodynamic assessment of nonculprit lesions with
fractional ﬂow reserve or an anatomic evaluation of
plaque vulnerability with intravascular ultrasound or
optical coherence tomography may offer an advan-
tage over angiography alone in guiding preventive
PCI during STEMI.
CONCLUSIONS
Patients with STEMI and MV-CAD are at signiﬁcant
risk of future adverse cardiovascular events. Whether
MV-PCI affects the natural history and prognosis of
these high-risk patients remains controversial. The
current practice guidelines do not advocate the
practice of MV intervention at the time of primary PCI
in the absence of hemodynamic compromise (7).
However, the literature from which the guidelines are
derived is largely retrospective and nonrandomized
trial data. The recent PRAMI investigation suggests
that an aggressive approach with preventive PCI may
lead to improved cardiovascular outcomes in STEMI
patients with MV-CAD, but this trial did not allow for
a strategy of staged PCI of nonculprit lesions. Thus,
the question remains: which patients with signiﬁcant
residual disease should have additional interventions
on an elective basis? Larger randomized clinical trials
are needed to further address the question of the
timing of nonculprit lesion PCI in this clinical context
and to help clarify which patients may derive the
most beneﬁt.
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